Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients

By Tsuge Masataka   Murakami Eisuke   Imamura Michio   Abe Hiromi   Miki Daiki   Hiraga Nobuhiko   Takahashi Shoichi   Ochi Hidenori   Nelson Hayes C.   Ginba Hiroyuki   Matsuyama Kazuhiro   Kawakami Hiroiku   Chayama Kazuaki  

Journal of Gastroenterology, Vol. 48, Iss. 10, 2013-10 ,pp. : 1188-1204

Springer Publishing Company

Access to resources Recommend Favorite

Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C

By Asahina Y.   Izumi N.   Uchihara M.   Noguchi O.   Nishimura Y.   Inoue K.   Ueda K.   Tsuchiya K.   Hamano K.   Itakura J.   Miyake S.  

Journal of Hepatology, Vol. 39, Iss. 6, 2003-12 ,pp. : 1063-1069

Elsevier

Access to resources Recommend Favorite

Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients

By  

Digestion, Vol. 84, Iss. 1, 2011-12 ,pp. : 23-28

Karger

Access to resources Recommend Favorite

Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B

By Papadopoulos Vasileios   Protopapas Andreas   Tsianos Epameinondas   Mimidis Konstantinos  

Scandinavian Journal of Gastroenterology, Vol. 44, Iss. 8, 2009-08 ,pp. : 1021-1022

Informa Healthcare

Access to resources Recommend Favorite

Prediction of Response to Pegylated Interferon/Ribavirin Combination Therapy for Chronic Hepatitis C Genotypes 2a and 2b and High Viral Load

By  

Digestive Diseases, Vol. 31, Iss. 5-6, 2013-11 ,pp. : 426-433

Karger

Access to resources Recommend Favorite